Join to View Full Profile
9500 Gilman Dr"# MC0612"La Jolla, CA 92093
Phone+1 858-822-3490
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Gerald Morris, MD is a board certified pathologist in La Jolla, California. He is currently licensed to practice medicine in California. He is affiliated with UCI Health and is an Instructor at Washington University School of Medicine.
Education & Training
Washington University/B-JH/SLCH ConsortiumResidency, Pathology-Anatomic and Clinical, 2006 - 2009
Wayne State University School of MedicineClass of 2006
Certifications & Licensure
CA State Medical License 2013 - 2027- CA State Medical License 2013 - 2027
American Board of Pathology Pathology - Clinical
Publications & Presentations
PubMed
- Follow-up biopsies with microvascular inflammation and persistent donor specific antibodies identify ongoing rejection in pediatric kidney transplant recipients.Clarkson Crane, Janara Mehrabli, Natalie Ellington, Katayoon Shayan, Gerald P Morris
Pediatric Nephrology. 2025-07-01 - 2 citationsSurveillance donor-specific antibody and pathologic antibody-mediated rejection testing in heart transplant patients in the contemporary era.Vincenzo Cusi, Ashley Cardenas, Yuko Tada, Florin Vaida, Nicholas Wettersten
The Journal of Heart and Lung Transplantation. 2025-07-01 - 3 citationsThe Impact of HLA-DQαβ Heterodimer Mismatch on Living Donor Kidney Allograft Outcomes.Olga Charnaya, Tanveen Ishaque, Andrew Hallett, Gerald P Morris, Myra Coppage
Transplantation. 2025-04-01
Grant Support
- T Cell Alloreactivity and Organ Transplant Risk Stratification Models Using High-Resolution HLA and Genomic DataUNIVERSITY OF CALIFORNIA, SAN DIEGO2025–2030
- Development of novel model to measure TCR signal strength in dual TCR cellsUNIVERSITY OF CALIFORNIA, SAN DIEGO2025–2027
- Use of allogeneic pMHCII-based 5MCAR-CTLs to eliminate alloreactive lymphocytes in transplantUNIVERSITY OF CALIFORNIA, SAN DIEGO2024–2026
- Use of allogeneic pMHCII-based 5MCAR-CTLs to eliminate alloreactive lymphocytes in transplantUNIVERSITY OF CALIFORNIA, SAN DIEGO2024–2026
- Dual TCR Expression Effects on Alloreactivity and TransplantationUNIVERSITY OF CALIFORNIA, SAN DIEGO2020–2025
